Ratings EL.En. S.p.A. Deutsche Boerse AG

Equities

EE5

IT0005453250

Real-time Estimate Tradegate Other stock markets 03:38:53 03/07/2024 pm IST			5-day change	1st Jan Change
9.445 ^EUR	+2.72%		0.00%	-4.76%

16/05	Transcript : EL.En. S.p.A., Q1 2024 Earnings Call, May 16, 2024
15/05	EL.En. S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

Revenue estimates are regularly revised downwards for the current and coming years.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
EL.EN. S.P.A.	-4.76%	81Cr		-
SISRAM MEDICAL LTD	-33.08%	21Cr		-
LAMEDITECH CO., LTD.	0.00%	11Cr	-	-
LASEROPTEK CO., LTD.	-30.64%	7.98Cr	-	-
MODULIGHT OYJ	-0.34%	5.26Cr		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes